Hangzhou Diagens Biotechnology Co., Ltd. (2526.HK) Stock Competitors & Peer Comparison
See (2526.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2526.HK | HK$288.80 | -12.48% | 25.7B | -328.18 | -HK$0.88 | N/A |
| 2697.HK | HK$633.00 | -12.45% | 22.6B | -230.89 | -HK$2.74 | N/A |
| 2252.HK | HK$20.06 | -17.11% | 20.6B | -75.50 | -HK$0.27 | N/A |
| 0853.HK | HK$6.66 | -6.46% | 12.7B | 34.74 | HK$0.19 | N/A |
| 2675.HK | HK$36.60 | -12.31% | 12B | -140.77 | -HK$0.26 | N/A |
| 1609.HK | HK$137.80 | -12.23% | 6.4B | 47.68 | HK$2.89 | N/A |
| 6606.HK | HK$14.14 | +0.00% | 6.3B | 25.05 | HK$0.56 | N/A |
| 1789.HK | HK$5.83 | -2.67% | 6.2B | 17.59 | HK$0.33 | +2.02% |
| 2190.HK | HK$19.53 | -4.08% | 6.1B | 38.51 | HK$0.51 | +1.85% |
| 1763.HK | HK$16.80 | -4.49% | 5.4B | 10.00 | HK$1.68 | +2.08% |
Stock Comparison
2526.HK vs 2697.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2697.HK has a market cap of 22.6B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2697.HK trades at HK$633.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2697.HK's P/E ratio is -230.89. In terms of profitability, 2526.HK's ROE is N/A, compared to 2697.HK's ROE of N/A. Regarding short-term risk, 2526.HK is more volatile compared to 2697.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2697.HK's competition here
2526.HK vs 2252.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2252.HK has a market cap of 20.6B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2252.HK trades at HK$20.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2252.HK's P/E ratio is -75.50. In terms of profitability, 2526.HK's ROE is N/A, compared to 2252.HK's ROE of -0.53%. Regarding short-term risk, 2526.HK is more volatile compared to 2252.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2252.HK's competition here
2526.HK vs 0853.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 0853.HK has a market cap of 12.7B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 0853.HK trades at HK$6.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 0853.HK's P/E ratio is 34.74. In terms of profitability, 2526.HK's ROE is N/A, compared to 0853.HK's ROE of +0.06%. Regarding short-term risk, 2526.HK is more volatile compared to 0853.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 0853.HK's competition here
2526.HK vs 2675.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2675.HK has a market cap of 12B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2675.HK trades at HK$36.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2675.HK's P/E ratio is -140.77. In terms of profitability, 2526.HK's ROE is N/A, compared to 2675.HK's ROE of N/A. Regarding short-term risk, 2526.HK is more volatile compared to 2675.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2675.HK's competition here
2526.HK vs 1609.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 1609.HK has a market cap of 6.4B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 1609.HK trades at HK$137.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 1609.HK's P/E ratio is 47.68. In terms of profitability, 2526.HK's ROE is N/A, compared to 1609.HK's ROE of N/A. Regarding short-term risk, 2526.HK is more volatile compared to 1609.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 1609.HK's competition here
2526.HK vs 6606.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 6606.HK has a market cap of 6.3B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 6606.HK trades at HK$14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 6606.HK's P/E ratio is 25.05. In terms of profitability, 2526.HK's ROE is N/A, compared to 6606.HK's ROE of -0.04%. Regarding short-term risk, 2526.HK is less volatile compared to 6606.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2526.HK.Check 6606.HK's competition here
2526.HK vs 1789.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 1789.HK has a market cap of 6.2B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 1789.HK trades at HK$5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 1789.HK's P/E ratio is 17.59. In terms of profitability, 2526.HK's ROE is N/A, compared to 1789.HK's ROE of +0.12%. Regarding short-term risk, 2526.HK is more volatile compared to 1789.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 1789.HK's competition here
2526.HK vs 2190.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2190.HK has a market cap of 6.1B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2190.HK trades at HK$19.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2190.HK's P/E ratio is 38.51. In terms of profitability, 2526.HK's ROE is N/A, compared to 2190.HK's ROE of +0.08%. Regarding short-term risk, 2526.HK is more volatile compared to 2190.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2190.HK's competition here
2526.HK vs 1763.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 1763.HK has a market cap of 5.4B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 1763.HK trades at HK$16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 1763.HK's P/E ratio is 10.00. In terms of profitability, 2526.HK's ROE is N/A, compared to 1763.HK's ROE of +0.06%. Regarding short-term risk, 2526.HK is more volatile compared to 1763.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 1763.HK's competition here
2526.HK vs 1858.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 1858.HK has a market cap of 5.3B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 1858.HK trades at HK$8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 1858.HK's P/E ratio is 11.52. In terms of profitability, 2526.HK's ROE is N/A, compared to 1858.HK's ROE of +0.09%. Regarding short-term risk, 2526.HK is more volatile compared to 1858.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 1858.HK's competition here
2526.HK vs 2172.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2172.HK has a market cap of 5.1B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2172.HK trades at HK$8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2172.HK's P/E ratio is 24.96. In terms of profitability, 2526.HK's ROE is N/A, compared to 2172.HK's ROE of +0.10%. Regarding short-term risk, 2526.HK is more volatile compared to 2172.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2172.HK's competition here
2526.HK vs 2235.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2235.HK has a market cap of 2.9B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2235.HK trades at HK$7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2235.HK's P/E ratio is 64.65. In terms of profitability, 2526.HK's ROE is N/A, compared to 2235.HK's ROE of +0.02%. Regarding short-term risk, 2526.HK is more volatile compared to 2235.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2235.HK's competition here
2526.HK vs 9996.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 9996.HK has a market cap of 2.7B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 9996.HK trades at HK$4.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 9996.HK's P/E ratio is -11.13. In terms of profitability, 2526.HK's ROE is N/A, compared to 9996.HK's ROE of -0.11%. Regarding short-term risk, 2526.HK is more volatile compared to 9996.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 9996.HK's competition here
2526.HK vs 6669.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 6669.HK has a market cap of 2.3B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 6669.HK trades at HK$7.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 6669.HK's P/E ratio is 11.93. In terms of profitability, 2526.HK's ROE is N/A, compared to 6669.HK's ROE of +0.08%. Regarding short-term risk, 2526.HK is more volatile compared to 6669.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 6669.HK's competition here
2526.HK vs 6609.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 6609.HK has a market cap of 1.5B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 6609.HK trades at HK$40.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 6609.HK's P/E ratio is 253.69. In terms of profitability, 2526.HK's ROE is N/A, compared to 6609.HK's ROE of +0.07%. Regarding short-term risk, 2526.HK is more volatile compared to 6609.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 6609.HK's competition here
2526.HK vs 1696.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 1696.HK has a market cap of 1.1B. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 1696.HK trades at HK$2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 1696.HK's P/E ratio is 7.94. In terms of profitability, 2526.HK's ROE is N/A, compared to 1696.HK's ROE of +0.04%. Regarding short-term risk, 2526.HK is more volatile compared to 1696.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 1696.HK's competition here
2526.HK vs 2407.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2407.HK has a market cap of 724.7M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2407.HK trades at HK$4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2407.HK's P/E ratio is 7.34. In terms of profitability, 2526.HK's ROE is N/A, compared to 2407.HK's ROE of +0.06%. Regarding short-term risk, 2526.HK is more volatile compared to 2407.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2407.HK's competition here
2526.HK vs 6922.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 6922.HK has a market cap of 614M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 6922.HK trades at HK$4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 6922.HK's P/E ratio is -21.68. In terms of profitability, 2526.HK's ROE is N/A, compared to 6922.HK's ROE of N/A. Regarding short-term risk, 2526.HK is more volatile compared to 6922.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 6922.HK's competition here
2526.HK vs 2160.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2160.HK has a market cap of 516.3M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2160.HK trades at HK$1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2160.HK's P/E ratio is 96.07. In terms of profitability, 2526.HK's ROE is N/A, compared to 2160.HK's ROE of -0.07%. Regarding short-term risk, 2526.HK is more volatile compared to 2160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2160.HK's competition here
2526.HK vs 1612.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 1612.HK has a market cap of 474.6M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 1612.HK trades at HK$0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 1612.HK's P/E ratio is 5.36. In terms of profitability, 2526.HK's ROE is N/A, compared to 1612.HK's ROE of +0.16%. Regarding short-term risk, 2526.HK is more volatile compared to 1612.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 1612.HK's competition here
2526.HK vs 2170.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2170.HK has a market cap of 361.1M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2170.HK trades at HK$1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2170.HK's P/E ratio is -1.00. In terms of profitability, 2526.HK's ROE is N/A, compared to 2170.HK's ROE of -0.23%. Regarding short-term risk, 2526.HK is more volatile compared to 2170.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2170.HK's competition here
2526.HK vs 2216.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2216.HK has a market cap of 352.8M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2216.HK trades at HK$0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2216.HK's P/E ratio is -2.45. In terms of profitability, 2526.HK's ROE is N/A, compared to 2216.HK's ROE of -0.12%. Regarding short-term risk, 2526.HK is more volatile compared to 2216.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2216.HK's competition here
2526.HK vs 6118.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 6118.HK has a market cap of 338.3M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 6118.HK trades at HK$0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 6118.HK's P/E ratio is 19.71. In terms of profitability, 2526.HK's ROE is N/A, compared to 6118.HK's ROE of +0.04%. Regarding short-term risk, 2526.HK is more volatile compared to 6118.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 6118.HK's competition here
2526.HK vs 2297.HK Comparison July 2026
2526.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2526.HK stands at 25.7B. In comparison, 2297.HK has a market cap of 332.1M. Regarding current trading prices, 2526.HK is priced at HK$288.80, while 2297.HK trades at HK$0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2526.HK currently has a P/E ratio of -328.18, whereas 2297.HK's P/E ratio is -3.39. In terms of profitability, 2526.HK's ROE is N/A, compared to 2297.HK's ROE of -0.20%. Regarding short-term risk, 2526.HK is more volatile compared to 2297.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2526.HK.Check 2297.HK's competition here